There is increasing evidence to suggest that metabotropic glutamate (mGlu) receptors including mGlu(7) receptor are important in the pathophysiology of stress-related psychiatric disorders such as anxiety and major depression. mGlu(7) receptor is highly expressed in the hippocampus, a key region involved in the modulation of depression-related behaviour. Moreover, mice deficient in mGlu(7) receptor have an antidepressant-like behaviour and altered stress response. To our knowledge there is little information as to whether stressful phenotypes can influence hippocampal mGlu(7) receptor levels. To this end, we examined hippocampal mGlu(7) receptor mRNA expression in two models of depression, the stress-sensitive Wistar Kyoto (WKY) and the maternally separated model of early-life stress. In situ hybridization analysis revealed that the WKY, but not the maternally separated (MS) rats displayed selective increases in mGlu(7) receptor mRNA expression in subregions of the hippocampus compared to relevant controls. These data suggest that higher levels of this receptor could affect the behaviour in response to stressful conditions and may play a role in WKY animal's susceptibility to stress-related disorders. However, the data in maternally separated animals confirm that whilst hippocampal mGlu(7) receptors maybe involved in certain aspects of stress biology, an increased expression is not necessary for the manifestation of depression-related phenotype per se.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2010.07.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evidence for functional interaction between the CB1 and the mGlu7 receptors mediated signaling in modulation of anxiety behavior and cognition.
Life Sci
January 2025
Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland. Electronic address:
Anxiety is a severe social problem. It is a disease entity that occurs alone or accompanies other diseases such as depression, phobia, or post-traumatic stress disorder. Our earlier studies demonstrated that blockage of arachidonic acid (AA) pathway via inhibition of cyclooxygenase-2 (COX-2) enzyme can modulate mGluRs-induced anxiety-like behavior.
View Article and Find Full Text PDFRadiosynthesis and preclinical evaluation of a carbon-11 labeled PET ligand for imaging metabotropic glutamate receptor 7.
Am J Nucl Med Mol Imaging
October 2024
Department of Radiology and Imaging Sciences, Emory University Atlanta, GA 30322, USA.
Metabotropic glutamate receptor 7 (mGlu) is a G protein-coupled receptor that is preferentially found in the active zone of neurotransmitter release in the central nervous system (CNS). mGlu plays a vital role in memory, learning, and neuronal development, rendering it a potential target for treating epilepsy, depression, and anxiety. The development of noninvasive imaging ligands targeting mGlu could help elucidate the functional significance of mGlu and accelerate drug discovery for neurological and psychiatric disorders.
View Article and Find Full Text PDFmGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders.
Pharmacol Rep
December 2024
Maj Institute of Pharmacology, Department of Neurobiology, Polish Academy of Sciences, Smętna 12, Kraków, 31-343, Poland.
Neuroprotection, defined as safeguarding neurons from damage and death by inhibiting diverse pathological mechanisms, continues to be a promising approach for managing a range of central nervous system (CNS) disorders, including acute conditions such as ischemic stroke and traumatic brain injury (TBI) and chronic neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD), and multiple sclerosis (MS). These pathophysiological conditions involve excessive glutamatergic (Glu) transmission activity, which can lead to excitotoxicity. Inhibiting this excessive Glu transmission has been proposed as a potential therapeutic strategy for treating the CNS disorders mentioned.
View Article and Find Full Text PDFGRM7 deficiency, from excitotoxicity and neuroinflammation to neurodegeneration: Systematic review of GRM7 deficient patients.
Brain Behav Immun Health
August 2024
Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.
The metabotropic glutamate receptor 7 (mGluR7) is a presynaptic G-protein-coupled glutamate receptor that modulates neurotransmitter release and synaptic plasticity at presynaptic terminals. It is encoded by GRM7, and recently variants have been identified in patients with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), developmental delay (DD), intellectual disability (ID), and brain malformations. To gain updated insights into the function of GRM7 and the phenotypic spectrum of genetic variations within this gene, we conducted a systematic review of relevant literature utilizing PubMed, Web of Science, and Scopus databases.
View Article and Find Full Text PDFNovel Inhibitory Site Revealed by Mode of Action on the Metabotropic Glutamate 7 Receptor Venus Flytrap Domain.
J Med Chem
July 2024
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Université Paris Cité, CNRS UMR 8601, 75006 Paris, France.
Metabotropic glutamate (mGlu) receptors play a key role in modulating most synapses in the brain. The mGlu7 receptors inhibit presynaptic neurotransmitter release and offer therapeutic possibilities for post-traumatic stress disorders or epilepsy. Screening campaigns provided mGlu7-specific allosteric modulators as the inhibitor (Gee et al.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!